Michiko N. Fukuda
Sanford-Burnham-Prebys Medical Discovery Institute, USA
Biography
It is widely accepted that surfaces of the vasculature express varying tissue-specific receptors under different pathological conditions1. Oh et al. used subtractive proteomics analysis of malignant vs. normal vasculature to identify Annexin A1 (ANXA1) as a highly specific surface marker of malignant tumor vasculature 2, 3. Independently, in mouse studies we reported that IF7 peptide, IFLLWQR, which binds the ANXA1 N-terminus, functions as a tumor vasculature-targeted drug delivery vehicle after intravenous injection4-6. To enhance IF7 stability in vivo, we undertook mirror-image peptide phage display using a synthetic D-peptide representing the ANXA1 N-terminus as target. We then identified candidate L-peptide sequences, synthesized them using D-amino acids, and found that one peptide bound to the L-ANXA1 N-terminus. We designated that peptide dTIT7. When we injected mouse brain tumor
Abstract
Abstract : Use of annexin A1-binding peptides as an orally-administrable tumor vasculaturetargeting therapeutic